spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  LIALDA 

 HSMN NewsFeed - 23 Dec 2022
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 29 Mar 2016
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 8 Mar 2016
Medgenics Hires Rick Couch, Ph.D. to Vice President of Chemistry, Manufacturing and Controls
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2010
Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Dec 2007
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.